Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 701–800 of 1,002
Nam, S. H., Jeong, J., Che, X., Lim, K., Nam, H., Park, J., & Choi, J. (2011) · Bone · doi:10.1016/j.bone.2011.10.017 · Cited by 26
Yates, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2179-3 · Cited by 26
FLUVASTATIN INCREASES BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN
GOTOH, M., Mizuno, K., ONO, Y., & Takahashi, M. (2011) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.57.19 · Cited by 26
Erviti, J., Alonso, Á., Gorricho, J., & López, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002084 · Cited by 26
Mazzantini, M., Carpeggiani, P., d’Ascanio, A., Bombardieri, S., & Munno, O. D. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1341-z · Cited by 26
Muratore, M., Quarta, E., & Quarta, L. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s12139 · Cited by 26
Burnett‐Bowie, S. M., Saag, K. G., Sebba, A. I., de Papp, A. E., Chen, E., Rosenberg, E., & Greenspan, S. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1122 · Cited by 26
Lufkin, E. G., Sarkar, S., Kulkarni, P. M., Ciaccia, A. V., Siddhanti, S. R., Stock, J. L., & Plouffe, L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003071 · Cited by 26
Bone metabolism and the perimenopause
Sayegh, R. A., & Stubblefield, P. G. (2002) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(02)00012-8 · Cited by 26
Osteoporosis treatment in postmenopausal women with pre-existing fracture
Cheng, M.-H., Chen, J., Fuh, J., Lee, W.-L., & Wang, P. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.04.001 · Cited by 25
Leizaola‐Cardesa, I. O., Aguilar‐Salvatierra, A., González‐Jaranay, M., Moreu, G., Sala-Romero, M.-J., & Moreno, G. G. (2016) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.20927 · Cited by 25
Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis
Nuti, R. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.208 · Cited by 25
Boonen, S., Klemes, A. B., Zhou, X., & Lindsay, R. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02763.x · Cited by 25
Biochemical Markers of Bone Turnover
CAREY, J. J., Licata, A. A., & Delaney, M. F. (2006) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:4:3:197 · Cited by 25
Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients
Omata, Y., Hagiwara, F., Nishino, J., Matsudaira, K., Kadono, Y., Juji, T., Mori, T., Nakayama, H., Nagase, Y., Hirose, J., et al. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0552-8 · Cited by 25
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
Bianchi, G., & Sambrook, P. N. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802370912 · Cited by 25
Fardellone, P., Cortet, B., Legrand, É., Bresse, X., Bisot-Locard, S., Vigneron, A.-M., & Béresniak, A. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.04.009 · Cited by 25
Nonaka, K., Fukuda, S., Aoki, K., Yoshida, T., & Ohya, K. (2005) · Bone · doi:10.1016/j.bone.2005.08.012 · Cited by 25
Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis
Miller, P. D. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.12.2253 · Cited by 25
Review of Treatment Modalities for Postmenopausal Osteoporosis
Hamdy, R. C., Chesnut, C. H., Gass, M. L. S., Holick, M. F., Leib, E. S., Lewiecki, M. E., Maricic, M. J., & Watts, N. B. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000184921.53062.bf · Cited by 25
The use of intermittent human parathyroid hormone as a treatment for osteoporosis
Deal, C. L. (2004) · Current Rheumatology Reports · doi:10.1007/s11926-004-0083-3 · Cited by 25
Sarıoğlu, M., Tüzün, Ç., Ünlü, Z., Tıkız, C., Taneli, F., & Uyanık, B. S. (2004) · Rheumatology International · doi:10.1007/s00296-004-0544-z · Cited by 25
Fracture prevention in postmenopausal osteoporosis: a review of treatment options
McCarus, D. C. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000197807.08697.06 · Cited by 24
Napoli, N., Incalzi, R. A., Gennaro, G., Marcocci, C., Marfella, R., Papalia, R., Purrello, F., Ruggiero, C., Tarantino, U., Tramontana, F., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.01.019 · Cited by 24
Schini, M., Vilaça, T., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Bouxsein, M., Black, D. M., & Eastell, R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae068 · Cited by 24
Self-citationEllis, A. G., Reginster, J., Luo, X., Bushmakin, A. G., Williams, R., Sutradhar, S., Mirkin, S., & Jansen, J. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.908279 · Cited by 24
Self-citationEvaluating the Antifracture Efficacy of Bisphosphonates
Pazianas, M., Epstein, S., & Zaidi, M. (2009) · Reviews on Recent Clinical Trials · doi:10.2174/157488709788186030 · Cited by 24
Schousboe, J. T., Dowd, B. E., Davison, M. L., & Kane, R. L. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1141-5 · Cited by 24
Kanatsu, K., Aihara, E., OKAYAMA, M., Kato, S., & Takeuchi, K. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2003.03314.x · Cited by 24
Factors influencing the treatment of osteoporosis following fragility fracture
Bessette, L., Jean, S., Davison, K. S., Roy, S., Ste‐Marie, L., & Brown, J. P. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0898-x · Cited by 24
Boonen, S., Eastell, R., Su, G., Mesenbrink, P. G., Cosman, F., Cauley, J. A., Reid, I. R., Claessens, F., Vanderschueren, D., Lyles, K. W., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1605 · Cited by 24
Self-citationComparison of alendronate and raloxifene in postmenopausal women with osteoporosis
Sanad, Z. F., Ellakwa, H., & Desouky, B. (2011) · Climacteric · doi:10.3109/13697137.2010.537408 · Cited by 24
Domino Effect: mechanic factors role.
Nardi, A., Tarantino, U., Ventura, L., Armotti, P., Resmini, G., Cozzi, L., Tonini, G., Ramazzina, E., & Rossini, M. (2011) · Europe PMC (PubMed Central) · Cited by 24
High prevalence of vertebral deformities in elderly patients with early rheumatoid arthritis
Ursum, J., Britsemmer, K., van Schaardenburg, D., Lips, P. T. A. M., Dijkmans, B. A. C., & Lems, W. F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105957 · Cited by 24
Trends and determinants of prescription medication use for treatment of osteoporosis
Farley, J. F., & Blalock, S. J. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080248 · Cited by 24
Laster, A. J., & Lewiecki, E. M. (2007) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.04.002 · Cited by 24
IBANDRONATE: A POTENT NEW BISPHOSPHONATE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Papapoulos, S. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10518.x · Cited by 24
Prevention of Glucocorticoid-induced Osteoporosis
Saag, K. G. (2004) · Southern Medical Journal · doi:10.1097/00007611-200406000-00008 · Cited by 24
Clinical use of denosumab for the treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.533651 · Cited by 24
Osteoporosis Screening: Time to Take Responsibility
Mazanec, D. J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1047 · Cited by 24
Beard, M. K. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.643296 · Cited by 23
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday
Xu, L., ADAMS-HUET, B. A., POINDEXTER, J. R., & Maalouf, N. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3447-9 · Cited by 23
Anabolic treatments for osteoporosis in postmenopausal women
Hassan, N., Gregson, C. L., & Tobias, J. H. (2021) · Faculty Reviews · doi:10.12703/r/10-44 · Cited by 23
Ong, T. I. W., Lim, L., Chan, S. P., Chee, W. S. S., Ch’ng, A. S. H., Chong, E. G. M., Damodaran, P., Hew, F. L., Ibrahim, L., Khor, H. M., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.002 · Cited by 23
Mudano, A. S., Gary, L. C., de Oliveira, A., Melton, M. E., Wright, N. C., Curtis, J. R., Delzell, E., Harrington, T. M., Kilgore, M. L., Lewis, C. E., et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s44551 · Cited by 23
Huntjens, K. M., van Geel, T. A. C. M., van Helden, S. H., van den Bergh, J. P., Willems, P. C. P. H., Winkens, B., Geusens, P., & Brink, P. R. G. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-121 · Cited by 23
Cost Effectiveness of Screen-and-Treat Strategies for Low Bone Mineral Density
Schousboe, J. T. (2008) · Applied Health Economics and Health Policy · doi:10.2165/00148365-200806010-00001 · Cited by 23
Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
Müeller, D., Weyler, E.-J., & Gandjour, A. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826060-00005 · Cited by 23
Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease
Kostoff, R. N. (2014) · Scientometrics · doi:10.1007/s11192-014-1298-3 · Cited by 23
Rackoff, P. J. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4080 · Cited by 23
L’ostéoporose : épidémiologie, clinique et approches thérapeutiques
Fontana, A., & Delmas, P. D. (2001) · médecine/sciences · doi:10.1051/medsci/200117121297 · Cited by 23
Wilson, M. G. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00102-7 · Cited by 23
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis
Ding, H., Koinuma, N., Stevenson, M., Ito, M., & Monma, Y. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0794-4 · Cited by 22
Yeap, S. S., Hew, F. L., Damodaran, P., Chee, W. S. S., Lee, J. K., Goh, E. M. L., Mumtaz, M., Lim, H. H., & Chan, S. P. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.004 · Cited by 22
Shi, L., Min, N., Wang, F., & Xue, Q. (2019) · BioMed Research International · doi:10.1155/2019/2594149 · Cited by 22
Yang, J., Cosman, F., Stone, P. W., Li, M., & Nieves, J. W. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05588-6 · Cited by 22
PERSISTENCE WITH BISPHOSPHONATE THERAPY IN OLDER PEOPLE
de Melo, M. N., Qiu, F., Sykora, K., Juurlink, D. N., Laupacis, A., & Mamdani, M. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00758.x · Cited by 22
Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures
Goltz, L., Degenhardt, G. A., Maywald, U., Kirch, W., & Schindler, C. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3399 · Cited by 22
Ste‐Marie, L., Brown, J. P., Beary, J. F., Matzkin, E., Darbie, L. M., Burgio, D. E., & Racewicz, A. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.012 · Cited by 22
Treating Osteoporosis with Bisphosphonates and Addressing Adherence: A Review of Oral Ibandronate
Chesnut, C. H. (2006) · Drugs · doi:10.2165/00003495-200666100-00004 · Cited by 22
Candida-associated gastric ulcer relapsing in a different position with a different appearance
Sasaki, K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i32.4450 · Cited by 22
This study is on behalf of the BEST investigators, Ghirardi, A., Bari, M. D., Zambon, A., Scotti, L., Vedova, G. D., Lapi, F., Cipriani, F., Caputi, A. P., Vaccheri, A., et al. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1708-8 · Cited by 22
Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?
Ryder, K. M., Cummings, S. R., Palermo, L., Satterfield, S., Bauer, D. C., Feldstein, A. C., Schousboe, J. T., Schwartz, A. V., & Ensrud, K. E. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0622-0 · Cited by 22
Osteoporosis: how long should we treat?
Sebba, A. I. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328317ca83 · Cited by 22
Osteopenia: A Diagnostic and Therapeutic Challenge
Lems, W. F., Raterman, H. G., van den Bergh, J. P., Bijlsma, H. W. J., Valk, N. K., Zillikens, M. C., & Geusens, P. (2011) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0062-3 · Cited by 22
Epstein, S., Delmas, P. D., Emkey, R. D., Wilson, K., Hiltbrunner, V., & Schimmer, R. C. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.01.011 · Cited by 22
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Lewiecki, M. E. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5645 · Cited by 22
Li, Z., & Meredith, M. P. (2003) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-120024209 · Cited by 22
Grima, D. T., Παπαϊωάννου, Α., Thompson, M. F., Pasquale, M. K., & Adachi, J. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0504-z · Cited by 22
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis
Body, J. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.4.567 · Cited by 22
Risedronate for the prevention and treatment of postmenopausal osteoporosis
Cranney, A., Adachi, J., Guyatt, G. H., Παπαϊωάννου, Α., Robinson, V., Shea, B., Tugwell, P., Waldegger, L., Weaver, B., Wells, G. A., et al. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub2 · Cited by 22
Hagino, H., Yoshida, S., Hashimoto, J., Matsunaga, M., Tobinai, M., & Nakamura, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9927-7 · Cited by 21
CHENG, C. K., McDonald-Blumer, H., Boire, G., Pope, J. E., Haraoui, B. P., Hitchon, C. A., Thorne, C., Sun, Y., & Bykerk, V. P. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.091368 · Cited by 21
Monoclonal antibodies for the treatment of osteoporosis
Lewiecki, E. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.740006 · Cited by 21
Vis, M., Bultink, I. E. M., Dijkmans, B. A. C., & Lems, W. F. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1862-z · Cited by 21
Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia
LAU, E. M. C., Sambrook, P. N., Seeman, E., Leong, K. H., Leung, P., & Delmas, P. D. (2006) · APLAR Journal of Rheumatology · doi:10.1111/j.1479-8077.2006.00161.x · Cited by 21
Diagnosis and treatment of osteoporosis
Park, Y. (2012) · Journal of Korean Medical Association · doi:10.5124/jkma.2012.55.11.1083 · Cited by 21
Pharmacological Mechanisms of Therapeutics
Hanley, D. A., Watson, P. H., Hodsman, A. B., & Dempster, D. W. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00085-9 · Cited by 21
Selby, P. L. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0018-y · Cited by 21
van der Linden, J. C., Verhaar, J. A. N., Pols, H. A. P., & Weinans, H. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2151-x · Cited by 21
Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis
Woo, T., & Adachi, J. D. (2001) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2001.0161 · Cited by 21
Werkman, C., Senra, G. S., da Rocha, R. F., & Brandão, A. A. H. (2006) · Brazilian Oral Research · doi:10.1590/s1806-83242006000300003 · Cited by 21
Efficacy and Tolerability of Alendronate Once Weekly in Asian Postmenopausal Osteoporotic Women
Ho, A. Y. Y., & Kung, A. W. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e580 · Cited by 21
Evaluation and treatment of postmenopausal osteoporosis.
Wang, C. Y., Bruder, J., & Rubin, C. D. (2001) · PubMed · Cited by 21
Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis: A Comparative Review
Kherani, R. B., Παπαϊωάννου, Α., & Adachi, J. D. (2002) · Drug Safety · doi:10.2165/00002018-200225110-00003 · Cited by 21
Fiechtner, J. J. (2003) · Postgraduate Medicine · doi:10.3810/pgm.2003.09.1489 · Cited by 21
Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site
Epstein, S. (2000) · Aging Clinical and Experimental Research · doi:10.1007/bf03339858 · Cited by 21
Aurich‐Barrera, B., Wilton, L., Harris, S., & Shakir, S. (2006) · Drug Safety · doi:10.2165/00002018-200629020-00005 · Cited by 21
Denosumab – an emerging treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604708 · Cited by 21
Bisphosphonates in the Management of Postmenopausal Osteoporosis
Papapoulos, S. E. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50073-8 · Cited by 21
The Role of Calcium in Osteoporosis Drug Therapy
Sunyecz, J. A., & Weisman, S. M. (2005) · Journal of Women s Health · doi:10.1089/jwh.2005.14.180 · Cited by 21
Rational use of oral bisphosphonates for the treatment of osteoporosis
Mathoo, J., Cranney, A., Παπαϊωάννου, Α., & Adachi, J. D. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0010-6 · Cited by 21
Rodríguez, A. J., & Abrahamsen, B. (2021) · JBMR Plus · doi:10.1002/jbm4.10522 · Cited by 20
Messner, Z., Vázquez, D. C., Haschka, J., Grillari, J., Resch, H., Muschitz, C., Pietschmann, P., Zwerina, J., Hackl, M., & Kocijan, R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac667 · Cited by 20
Eastell, R. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.017 · Cited by 20
Self-citationReview of risedronate in the treatment of osteoporosis
McClung, M. R., & Geusens, P. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.12.2011 · Cited by 20
Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis
Chao, M., Hua, Q., Yingfeng, Z., Guang, W., Shufeng, S., Dong, Y., Wang, W., & Haifeng, T. (2013) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.296.3677 · Cited by 20
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Choi, H. S., Park, S. Y., Kim, Y. M., Kim, S. H., Kim, K. M., & Chung, Y. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.003 · Cited by 20
Rabenda, V., & Reginster, J. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1155-z · Cited by 20
Self-citation
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.